IC
CYCN icon

Ikarian Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Ikarian Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,373
Closed -$585K – 158
2022
Q1 		$585K Buy
26,373
+1,242
+5% +$29.9K 0.08% 125
2021
Q4 		$866K Hold
25,131
– – 0.13% 104
2021
Q3 		$1.54M Sell
25,131
-365
-1% -$23.9K 0.11% 139
2021
Q2 		$1.99M Buy
25,496
+10,496
+70% +$657K 0.16% 127
2021
Q1 		$836K Buy
+15,000
New +$1.13M 0.03% 241

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Ikarian Capital's CYCN Position: Q2 2022 in Review

Ikarian Capital sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 26,373 shares — an estimated $585K sold.

Ikarian Capital first reported a position in CYCN in Q1 2021 and held it in 5 quarters. The position peaked at $1.99M in Q2 2021. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • Ikarian Capital reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 26,373 Cyclerion Therapeutics shares in Q2 2022, an estimated $585K.
  • Ikarian Capital first reported a position in Cyclerion Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Cyclerion Therapeutics position peaked at $1.99M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.